AVM0703 is a proprietary formulation of dexamethasone that triggers the production and release of endogenous gamma delta+ Natural Killer T cells, eliminating abnormal cells, whether cancer or virus-infected, or autoreactive cells. AVM Biotechnology has a Scientific Advisory Board including well-respected leaders in cancer and immunology and is committed to developing products that improve outcomes without additional suffering.